BOULDER, Colo., Jan. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, February 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) 



    Conference Call Information

    Date:                                Tuesday, February 4, 2014

    Time:                                9:00 a.m. eastern time

    Toll-
     Free:                               (877) 261-8990

    Toll:                                (847) 619-6441

    Pass
     Code:                                                            36464298

    Webcast, including Replay and Conference Call Slides:  http://
     investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
    -----------------------------------------------------------------

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520), for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis). For more information on Array, please go to www.arraybiopharma.com



    CONTACT:                Tricia Haugeto

                            Array BioPharma Inc.

                            (303) 386-1193

                            thaugeto@arraybiopharma.com

SOURCE Array BioPharma Inc.